JP2024520690A - 皮膚神経線維腫の治療に使用するためのニトロキソリン - Google Patents

皮膚神経線維腫の治療に使用するためのニトロキソリン Download PDF

Info

Publication number
JP2024520690A
JP2024520690A JP2023574531A JP2023574531A JP2024520690A JP 2024520690 A JP2024520690 A JP 2024520690A JP 2023574531 A JP2023574531 A JP 2023574531A JP 2023574531 A JP2023574531 A JP 2023574531A JP 2024520690 A JP2024520690 A JP 2024520690A
Authority
JP
Japan
Prior art keywords
composition
nitroxoline
use according
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520690A5 (enExample
Inventor
ブラウン デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of JP2024520690A publication Critical patent/JP2024520690A/ja
Publication of JP2024520690A5 publication Critical patent/JP2024520690A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023574531A 2021-06-09 2022-06-09 皮膚神経線維腫の治療に使用するためのニトロキソリン Pending JP2024520690A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108224.3 2021-06-09
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment
PCT/GB2022/051442 WO2022258972A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Publications (2)

Publication Number Publication Date
JP2024520690A true JP2024520690A (ja) 2024-05-24
JP2024520690A5 JP2024520690A5 (enExample) 2025-06-12

Family

ID=76838879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574531A Pending JP2024520690A (ja) 2021-06-09 2022-06-09 皮膚神経線維腫の治療に使用するためのニトロキソリン

Country Status (12)

Country Link
US (1) US20240261276A1 (enExample)
EP (1) EP4351576A1 (enExample)
JP (1) JP2024520690A (enExample)
KR (1) KR20240024175A (enExample)
CN (1) CN117769419A (enExample)
AU (1) AU2022290019A1 (enExample)
BR (1) BR112023025789A2 (enExample)
CA (1) CA3221964A1 (enExample)
GB (1) GB202108224D0 (enExample)
IL (1) IL309177A (enExample)
MX (1) MX2023014530A (enExample)
WO (1) WO2022258972A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202116743D0 (en) * 2021-11-19 2022-01-05 Healx Ltd Treatment
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514705A (ja) * 2013-03-15 2016-05-23 アジエリス ファーマシューティカル テクノロジーズ コンパニー リミテッド ニトロキソリンの塩基付加塩及びその使用
WO2020106306A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2021023231A1 (zh) * 2019-08-05 2021-02-11 江苏亚虹医药科技股份有限公司 含硝羟喹啉的药物组合物、硝羟喹啉口服固体片剂及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3287905A1 (en) * 2016-10-14 2025-11-29 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514705A (ja) * 2013-03-15 2016-05-23 アジエリス ファーマシューティカル テクノロジーズ コンパニー リミテッド ニトロキソリンの塩基付加塩及びその使用
WO2020106306A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2021023231A1 (zh) * 2019-08-05 2021-02-11 江苏亚虹医药科技股份有限公司 含硝羟喹啉的药物组合物、硝羟喹啉口服固体片剂及其制备方法和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIA, JING ET AL.: ""Activated androgen receptor accelerates angiogenesis in cutaneous neurofibroma by regulating VEGFA", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 55, JPN6026022545, 6 May 2019 (2019-05-06), pages 157 - 166, ISSN: 0005875164 *
SHIM, JOONG SUP ET AL.: ""Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer"", JNCI: JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 102, no. 24, JPN6026022544, 18 November 2010 (2010-11-18), pages 1855 - 1873, ISSN: 0005875162 *
VERMA, SHARAD K. ET AL.: ""Considerations for development of therapies for cutaneous neurofibroma"", NEUROLOGY, vol. Vol. 91，No. 2_Supplement_1, JPN6026022546, 10 July 2018 (2018-07-10), pages 21 - 30, ISSN: 0005875163 *

Also Published As

Publication number Publication date
MX2023014530A (es) 2024-04-10
US20240261276A1 (en) 2024-08-08
BR112023025789A2 (pt) 2024-02-27
CA3221964A1 (en) 2022-12-15
WO2022258972A1 (en) 2022-12-15
CN117769419A (zh) 2024-03-26
EP4351576A1 (en) 2024-04-17
AU2022290019A1 (en) 2023-12-14
IL309177A (en) 2024-02-01
KR20240024175A (ko) 2024-02-23
GB202108224D0 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
KR102698911B1 (ko) 근육 질환을 예방하거나 치료하기 위한 조성물 및 방법
US7405227B2 (en) Treatment of cancer
HUP0302677A2 (hu) Módszer a fájdalom megszüntetésére
Gisondi et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events
JP2010132691A (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
JP2006512281A (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
JP2024540177A (ja) ヘンプ抽出物を使用する子宮内膜がんを処置する方法
US20240261276A1 (en) Nitroxoline for use in the treatment of cutaneous neurofibroma
CN113194946B (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
JP2024540439A (ja) 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン
KR102174191B1 (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
WO2021260387A1 (en) Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
CN101039674A (zh) 河豚毒素及其衍生物用于治疗中枢神经源性神经痛
US8633250B2 (en) Cell repair and regeneration by suramin and related polysulfonated napthylureas
US12599617B2 (en) Methods of treating head and neck cancers with hemp extract
KR20150083167A (ko) 메틸렌 블루를 포함하는 감각신경성 난청의 치료 또는 예방용 약학 조성물
US20180086827A1 (en) Therapeutics and methods of treating fibroproliferative diseases
WO2022042527A1 (zh) 治疗内耳及肠道上皮组织损伤相关疾病的小分子药物
CN120322233A (zh) 用于在恶性周围神经鞘瘤的治疗或预防中使用的硝羟喹啉
HK1120441B (en) Drugs for treatment of ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260806